IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition marked by the accumulation of IgG4-positive plasma ...

Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the ...

Jefferies analyst Michael Yee maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $350.00. The company’s ...

Growth Drivers include demand for protein-based drugs, rise in chronic disease prevalence, precision medicine expansion, biotech advancements, and AI-driven design tools.Dublin, April 14, 2025 (GLOBE ...

Switzerland-based generic drug maker Sandoz said on Monday that it has filed an antitrust lawsuit against Amgen, Inc, (AMGN) ...

Amgen (AMGN) stock in focus as Sandoz files antitrust lawsuit alleging that the company blocked copycats from targeting its ...

Sandoz (SDZNY) announced the filing of an antitrust lawsuit in the U.S. against Amgen (AMGN), for extending and entrenching the dominant market ...

Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen ...

Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the U.S. against Amgen for ...

Shares of Amgen Inc. AMGN rose 1.62% to $285.98 Friday, on what proved to be an all-around great trading session for the ...

The bispecific antibody helped people with small cell lung cancer live longer, Amgen said. Elsewhere, J&J shared new autoimmune drug data and Alzheon reported an Alzheimer’s drug failure.

Big Pharma and biotech startups alike are counting on AI to speed the process of drug discovery and make their operations ...